Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | ERBB2 V773M |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
ERBB2 V773M | Advanced Solid Tumor | sensitive | Pyrotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Pyrotinib inhibited survival of transformed cells expressing ERBB2 (HER2) V773M in culture (PMID: 31588020). | 31588020 | |
ERBB2 V773M | Advanced Solid Tumor | sensitive | Dacomitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vizimpro (dacomitinib) inhibited survival of transformed cells expressing ERBB2 (HER2) V773M in culture (PMID: 31588020). | 31588020 | |
ERBB2 V773M | Advanced Solid Tumor | sensitive | Afatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gilotrif (afatinib) inhibited survival of transformed cells expressing ERBB2 (HER2) V773M in culture (PMID: 31588020). | 31588020 | |
ERBB2 V773M | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) V773M were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 | |
ERBB2 V773M | Advanced Solid Tumor | resistant | Osimertinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) V773M were resistant to Tagrisso (osimertinib) in culture (PMID: 31588020). | 31588020 | |
ERBB2 V773M | Advanced Solid Tumor | sensitive | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, Imbruvica (ibrutinib) inhibited survival of transformed cells expressing ERBB2 (HER2) V773M in culture (PMID: 31588020). | 31588020 | |
ERBB2 V773M | Advanced Solid Tumor | sensitive | TH-4000 | Preclinical - Cell culture | Actionable | In a preclinical study, Tarloxotinib (TH-4000) inhibited survival of transformed cells expressing ERBB2 (HER2) V773M in culture (PMID: 31588020). | 31588020 | |
ERBB2 V773M | Advanced Solid Tumor | resistant | Sapitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) V773M were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020). | 31588020 | |
ERBB2 V773M | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) V773M were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 | |
ERBB2 V773M | Advanced Solid Tumor | sensitive | Poziotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Poziotinib (HM781-36B) inhibited survival of transformed cells expressing ERBB2 (HER2) V773M in culture (PMID: 31588020). | 31588020 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04172597 | Phase II | Poziotinib | A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies | Recruiting |